Endometrial carcinoma

New England Journal of Medicine

Volumn 335, Issue 9, 1996, Pages 640-649

  Rose, Peter G ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL;

CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0029799612     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608293350907     Document Type: Review

References (100)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995;75:Suppl: 270-94.
3. Kosary CL, Reis LAG, Miller BA, Hankey BE, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1992, tables and graphs. Bethesda, Md.: National Cancer Institute, 1995 171-81 NIH publication no. 95-2789.)
4. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age and younger. Obstet Gynecol 1984,64 417-20.
5. Parazzini F, Negri E, La Vecchia C, Bruzzi P Decarli A Population attributable risk for endonetrial cancer in northern Italy. Eur J Cancer Clin Oncol 1989;25:1451-6.
6. Dubeau L. Etiology and detection of cancer. In: Morrow CP, Curtin JP, Townsend DE, eds. Synopsis of ayncologic oncology. 4th ed. New York: Churchill Livingstone, 1993:1-22.
7. Kurman RJ, Kaminski PF, Norris HJ. The behavior endometrial hyperplasia: a long-term study of "untreated" in 170 patients. Cancer 1985;56:403-12.
8. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680-6.
9. Bjorkholm E, Pettersson F. Granulosa-cell and cell tumors: the clinical picture and long-term outcome for the Radiuinhemmet series. Acta Obstet Gynecol Scand 1980;59:361-5.
10. Peterson EP Endometrial carcinoma in young women a clinical profile. Obstet Gynecol 1968;31:702-7.
11. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engi J Med 1976,294:1262-7.
12. Food and Drug Administration. Estrogens and endometrial cancer. FDA Drug Bull 1976;6:18-20.
13. McGonigle KF, Karlan BY, Barbuto DA. Leuchter RS, Lagasse LD, Judd HL. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol Oncol 1994;55: 126-32.
14. American College of Obstetricians and Gynecologists. Hormone replacement therapy. ACOG Technical Bulletin. No. 166, 1992.
15. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69: 237-8.
16. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. In: Boice JD Jr, Storm HH, Curtis RE, et al., eds. Multiple primary cancers in Connecticut and Denmark. National Cancer Institute monograph 68. Washington, D.C.: Government Printing Office, 1985:99-112. (NIH publication no. 85-2714.)
17. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
18. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
19. Andersson M, Storm HH, Mouridscn HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-7.
20. Oral contraceptive use and the risk of endometrial cancer: the Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983;249: 1600-4.
21. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617-31.
22. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
23. Lesko SM, Rosenberg L, Kaufman DW, et al. Cigarette smoking and the risk of endometrial cancer. N Engl J Med 1985;313:593-6.
24. Mecklin JP, Jarvinen HJ. Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). Cancer 1991;68:1109-12.
25. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-85.
26. Hawwa ZM, Nahhas WA, Copenhaver EH. Postmenopausal bleeding. Lahey Clin Found Bull 1970;19:61-70.
27. Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982;142:1-6.
28. Fleischer AC, Kalemeris GC, Machin JE, Entman SS, James AE Jr. Sonographic depiction of normal and abnormal endometrium and histopathologic correlation. J Ultrasound Med 1986;5:445-52.
29. Granberg S, Wikland M, Karlsson B, Norstom A, Friberg LG. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991;164:47-52.
30. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am J Obstet Gynecol 1995;172:1488-94.
31. Tsuda H, Kawabata M, Kawabata K, et al. Differences between Occidental and Oriental postmenopausal women in cutoff level of endometrial thickness for endometrial cancer screening by vaginal scan. Am J Obstet Gynecol 1995;172:1494-5.
32. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-4.
33. Van den Bosch T, Vandendael A, Van Schoubroeck D, Wranz PAB, Lombard CJ. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995;85:349-52.
34. Goldchmit R, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial Pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993;82:727-30.
35. Hunter RE, Reuter K, Kopin E. Use of ultrasonography in the difficult postmenopausal dilation and curettage. Obstet Gynecol 1989;73:813-6.
36. Gimpelson RJ, Rappold HO. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage: a review of 276 cases Am J Obstet Gynecol 1988;158:489-92.
37. Loffer FD. Hysteroscopy with selective endometrial sampling compared with D&C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 1989;73:16-20.
38. Archer DF, McIntyre-Seltman K, Wilborn WW Jr, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 1991;165:317-22.
39. Gronroos M, Salmi TA, Vuento MH, et al. Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension. Cancer 1993;71:1279-82.
40. Tamoxifen and endometrial cancer. In: ACOG Committee on Gynecologic Practice. Committee opinion. No. 169. Washington, D.C.: American College of Obstetricians and Gynecologists, 1996.
41. Gibson LE, Barakat RR, Venkatraman ES, Hoskins WJ. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J Sci Am 1996;2:35-8.
42. Mecklin P, Jarvinen H. Treatment and follow-up strategies in hereditary nonpolyposis colorectal carcinoma. Dis Colon Rectum 1993;36:927-9.
43. Houlston RS, Murday V, Harocopos C, Williams CB, Slack J. Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. BMJ 1990;301:366-8. [Erratum, BMJ 1990;301: 446.]
44. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway: a study of a total population. Cancer 1991;67:3093-103
45. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 patients. Am J Clin Pathol 1982;77:534-40.
46. Christopherson WM, Connelly PJ, Alberhasky RC. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 1983;51:1705-9.
47. Zaino RJ, Kurman R, Herbold D, et al. The significance of squamous differentiation in endometrial carcinoma: data from a Gynecologic Oncology Group study. Cancer 1991;68:2293-302.
48. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
49. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
50. Goff BA, Kato D, Schmidt RE, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-8.
51. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 1987;60:Suppl:2035-41.
52. Lewis BV, Stallworthy JA, Cowdell R. Adenocarcinoma of the body of the uterus. J Obstet Gynaecol Br Commonw 1970;77:343-8.
53. Harouny VR, Sutton GP, Clark SA, Geisler HE, Stehman FB, Ehrlich CE. The importance of peritoneal cytology in endometrial carcinoma. Obstet Gynecol 1988;72:394-8.
54. Lurain JR, Rumsey NK, Schink JC, Wallemark CB, Chmiel JS. Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1989:74:175-9.
55. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 1992;80:655-9.
56. Chen MD, Karlan BY, Muderspach LI, Walts AE, Lagasse LD. Is positive peritoneal cytology sufficient for stage IIIA endometrial cancer? In: Abstracts of current clinical and basic investigation of the 40th Annual Clinical Meeting, April 27-30, 1992. Washington, D.C.: American College of Obstetricians and Gynecologists Abstracts, 1992:13. abstract.
57. Hanson MB, van Nagell JR Jr, Powell DE, et al. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 1985;55:1753-7.
58. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
59. Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol 1987;70:216-9.
60. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
61. Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995;85:504-8.
62. Schottenfeld D. Determinants of black/white survival differences among women with endometrial cancer. Gynecol Oncol 1995;56:151-3.
63. Liu JR, Conaway M, Rodriguez GC, Soper JT, Clarke-Pearson DL, Berchuck A. Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol 1995;86:486-90.
64. Hill HA, Coates RJ, Austin H, et al. Racial differences in tumor grade among women with endometrial cancer. Gynecol Oncol 1995;56:154-63.
65. Barrett RJ H, Harlan LC, Wesley MN, et al. Endometrial cancer: stage at diagnosis and associated factors in black and white patients. Am J Obstet Gynecol 1995;173:414-23.
66. Aziz H, Rotman M, Hussain F, et al. Poor survival of black patients in carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 1993;27: 293-301.
67. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage - a Gynecologic Oncology Group study. Cancer 1996;77:1115-21.
68. Zaino RJ, Satyaswaroop PG, Mortel R. The relationship of histologic and histochemical parameters to progesterone receptor status in endometrial adenocarcinoma. Gynecol Oncol 1983;16:196-208.
69. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:Suppl:1467-70.
70. Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155: 770-6.
71. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
72. Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992;79:95-100.
73. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
74. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 Expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
75. Lukes AS, Kohler MF, Pieper CF, et al. Multivariate analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
76. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-34.
77. American College of Obstetricians and Gynecologists. Carcinoma of the endometrium. ACOG Technical Bulletin. No. 162. December 1991.
78. Gordon AN, Fleischer AC, Dudley SB, et al. Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI). Gynecol Oncol 1989;34: 175-9.
79. Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984;148:1057-8.
80. Patsner B, Mann WJ, Cohen H, Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 1988;158:399-402.
81. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA 125 measurements for evaluation of recurrence in pa tients with endometrial carcinoma. Obstet Gynecol 1994;84:12-6.
82. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33
83. Shim JU, Rose PG, Reale FR, Soto H, Tak WK, Hunter RE. Accuracy of frozen-section diagnosis at surgery in clinical stage I and II endometrial carcinoma. Am J Obstet Gynecol 1992;166:1335-8.
84. Doering DL, Barnhill DR, Weiser EB, Burke TW, Woodward JE, Park RC. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. Obstet Gynecol 1989;74:930-3.
85. Candiani GB, Belloni C, Maggi R, Colombo G, Frigoli A, Carinelli SG. Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I. Gynecol Oncol 1990;37:6-8.
86. Childers JM, Brzechffa RP, Hatch KD, Surwit EA. Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol Oncol 1993; 51:33-8.
87. Childers JM, Hatch KD, Tran A-N, Surwit EA. Laparoscopic para-aortic lymphadenectomy in gynecologic malignancies. Obstet Gynecol 1993; 82:741-7.
88. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56: 419-27.
89. Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011-6.
90. Varia M, Rosenman J, Halle J, Walton L, Currie J, Fowler W. Primary radiation therapy for medically inoperable patients with endometrial carcinoma - stages I-II. Int J Radiat Oncol Biol Phys 1987;13:11-5.
91. Rose PG, Baker S, Kern M, et al. Primary radiation therapy for endometrial carcinoma: a case controlled study. Int J Radiat Oncol Biol Phys 1993;27:585-90.
92. Bokhman JV, Chepick OF, Volkova AT, Vishncvsky AS. Can primary endometrial carcinoma stage I be treated without surgery and radiation therapy? Gynecol Oncol 1985;20:139-55.
93. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986;68:741-5.
94. Moore TD, Phillips PH, Nerenstonc SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 1991;9:1071-88.
95. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma: a review of clinical observations. Acta Obstet Gynecol Scand 1984; 63:441-50.
96. Thigpen T, Blessing J, Hatch K, Barrett R, Adelson M, Disaia P. A randomized trial of medroxyprogesterone acetate (MPA) 200 mg versus 1000 mg daily in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 1991;10:185. abstract.
97. Thigpen T, Blessing J, Homesley H, Malfetano J, Disaia P, Yordan E. Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 1993;12:261. abstract.
98. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of taxol in advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1995;56:120. abstract.
99. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-91.
100. Estrogen replacement therapy and endometrial cancer. In: ACOG Committee on Gynecologic Practice. Committee opinion. No. 126. Washington, D.C.: American College of Obstetricians and Gynecologists, 1993.